Stockreport

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics, Inc.  (KYMR) 
PDF KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the secon [Read more]